Compare Charles River Laboratories Intl. Inc (CRL) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Toyota Motor Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Toyota Motor Corp trades at $176.38 (market cap $205.39B). The key difference: Toyota Motor Corp is far larger — about 18.4× Charles River Laboratories Intl. Inc's market cap, and Toyota Motor Corp pays a 3.59% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | TM | |
|---|---|---|
Market Cap | $11.14B | $205.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $248.29 |
52-Week Low | $145.57 | $166.50 |
Enterprise Value | $14.00B | $369.58B |
Dividend Yield | — | 3.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Toyota Motor trades at $174.75, down 0.96% with neutral technical signals. The stock shows attractive valuation metrics including a P/E of 9.58 and P/B of 0.84, trading below industry averages. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $4.00 exceeding the $3.11 estimate. The company's $3.6 billion Texas expansion signals strong growth commitment amid positive hybrid vehicle sales momentum.
Toyota presents a compelling value opportunity with strong fundamentals and consistent earnings performance. However, declining profit margins and increasing debt levels warrant monitoring. Analyst consensus leans neutral with 62.5% hold ratings, suggesting cautious optimism about the company's strategic investments and hybrid leadership position in the evolving automotive landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
